Mari Ueda

Learn More
To improve treatment conformity for prostate cancer, we investigated daily applicator displacement during high-dose-rate interstitial brachytherapy (HDR-ISBT). Thirty patients treated with HDR-ISBT as monotherapy were examined. All patients received a treatment dosage of 49 Gy per 7 fractions over 4 days. For dose administration, we examined 376 flexible(More)
To expand the indications for high-dose-rate interstitial brachytherapy (HDR-ISBT) for deep-seated pelvic tumors, we investigated the usefulness of Doppler transrectal ultrasonography (TRUS) guidance and virtual planning. The patient was a 36-year-old female. She had right internal iliac lymph node oligometastasis of vaginal cancer 12 months after radical(More)
Accessibility information can allow disabled people to identify suitable pathways to reach their destinations, but it is difficult to obtain new accessible pathway information rapidly because of limited local information disclosure. Thus, it is necessary to develop a comprehensive system that acquires barrier-free information from various sources and makes(More)
PURPOSE To choose the optimal brachytherapeutic modality for uterine cervical cancer, we performed simulation analysis. METHODS AND MATERIALS For each high-risk clinical target volume (HR CTV), we compared four modalities [classical conventional intracavitary brachytherapy (ConvICBT), Image-guided ICBT (IGICBT), intracavitary/interstitial brachytherapy(More)
We investigated daily needle applicator displacement during multifractionated high-dose-rate interstitial brachytherapy (HDR-ISBT) for postoperative recurrent uterine cancer. Eight patients with postoperative recurrent uterine cancer received HDR-ISBT with or without external beam radiotherapy using our unique ambulatory technique. To analyze displacement,(More)
Due to the Great East Japan Earthquake on 11 March 2011 and the following long-term earthquake swarm, many people living in the earthquake-affected areas have developed mental stress, even though clinically-diagnosable symptoms may not be apparent. Concurrently, many unusual reports have emerged in which persons complain of abnormally increased sensitivity(More)
OBJECTIVE To evaluate the efficacy of primary treatment for ovarian cancer from overall survival and progression-free survival. PATIENTS AND METHODS A total of 28 patients with epithelial ovarian cancer in stages III and IV who were primarily treated in our ward from 1993 were examined retrospectively. The Kaplan-Meier method and Harrington-Fleming test(More)
  • 1